NCT06623422

AUG 10, 2026 · PHASE 3 TRIAL

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

ClinicalTrials.gov

This is an active Phase 3 trial registration with no posted results; the study design is rigorous but outcome data are not yet reported, making evidence assessment impossible.